Back to Search
Start Over
Comparison of quetiapine and risperidone in Chinese Han patients with schizophrenia: results of a single-blind, randomized study.
- Source :
-
Current medical research and opinion [Curr Med Res Opin] 2012 Oct; Vol. 28 (10), pp. 1725-32. Date of Electronic Publication: 2012 Oct 02. - Publication Year :
- 2012
-
Abstract
- Objective: To evaluate the efficacy and safety of 750 mg/day quetiapine fumarate (Seroquel) in the treatment of Chinese Han patients with schizophrenia.<br />Methods: In this 6-week, multicenter, randomized, rater single-blind study, a total of 119 patients with schizophrenia were randomly assigned to quetiapine (n = 60, 750 mg/day) or risperidone (n = 59, 4 mg/day). The efficacy was assessed by the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression-Change (CGI-C) and the Calgary Depression Scale for Schizophrenia (CDSS). Safety and tolerability assessments included treatment-emergent adverse events, laboratory tests and electrocardiograms.<br />Results: The primary analysis demonstrated no significant difference between treatment in the two groups (quetiapine vs. risperidone: 31.9 ± 17.5 vs. 33.3 ± 17.3; P = 0.668). Improvements with both treatments were comparable for total PANSS, positive and negative subscores, general psychopathology subscales, and excitement and attack symptoms. Improvements in CGI-S were similar between treatment groups (P = 0.046). A more favorable trend was detected for quetiapine than risperidone in the reduction of CDSS scores from baseline, especially at week 1 (1.1 ± 2.2 vs. 0.3 ± 2.1, P < 0.050). The rate of extrapyramidal symptom (EPS) and hyperprolactinemia-related adverse events was significantly lower in the quetiapine group than the risperidone group (13.3% vs. 43.3%, P < 0.001). Dizziness and somnolence were more common in the quetiapine group than the risperidone group.<br />Conclusion: Quetiapine fumarate (750 mg/day) has broad clinical efficacy comparable to 4 mg/day risperidone. Dizziness was common in the quetiapine group (P = 0.029), but the rate of somnolence was similar between the two groups (P = 0.114). EPS and hyperprolactinemia rates were significantly higher with risperidone (P < 0.001). Key limitations of this study include small sample size, short treatment periods, and no increase to 6 mg/day for risperidone because of its safety profile.
- Subjects :
- Adolescent
Adult
Aged
Antipsychotic Agents adverse effects
Asian People
China
Dibenzothiazepines adverse effects
Female
Humans
Hyperprolactinemia blood
Hyperprolactinemia chemically induced
Hyperprolactinemia ethnology
Hyperprolactinemia physiopathology
Male
Middle Aged
Quetiapine Fumarate
Risperidone adverse effects
Schizophrenia blood
Schizophrenia ethnology
Schizophrenia physiopathology
Time Factors
Antipsychotic Agents administration & dosage
Dibenzothiazepines administration & dosage
Risperidone administration & dosage
Schizophrenia drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1473-4877
- Volume :
- 28
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Current medical research and opinion
- Publication Type :
- Academic Journal
- Accession number :
- 22978771
- Full Text :
- https://doi.org/10.1185/03007995.2012.728524